LAVA Therapeutics (LVTX)
(Delayed Data from NSDQ)
$2.74 USD
+0.03 (1.11%)
Updated Apr 22, 2024 11:18 AM ET
After-Market: $2.88 +0.14 (5.11%) 7:58 PM ET
3-Hold of 5 3
C Value B Growth B Momentum B VGM
LAVA Therapeutics N.V. (LVTX) Price Targets
Average Price Target | Highest Price Target | Lowest Price Target | Upside to Average Price Target |
---|---|---|---|
$7.25 | $11.00 | $6.00 | 167.53% |
Price Target
Based on short-term price targets offered by four analysts, the average price target for LAVA Therapeutics N.V. comes to $7.25. The forecasts range from a low of $6.00 to a high of $11.00. The average price target represents an increase of 167.53% from the last closing price of $2.71.
Analyst Price Targets (4 )
Broker Rating
LAVA Therapeutics N.V. currently has an average brokerage recommendation (ABR) of 1.00 on a scale of 1 to 5 (Strong Buy to Strong Sell), calculated based on the actual recommendations (Buy, Hold, Sell etc.) made by four brokerage firms. The current ABR compares to an ABR of 1.00 a month ago based on four recommendations.
Of the four recommendations deriving the current ABR, four are Strong Buy, representing 100% of all recommendations. A month ago, Strong Buy represented 100%.
Broker Rating Breakdown
Brokerage Recommendations
Today | 1 Week Ago | 1 Month Ago | 2 Months Ago | 3 Months Ago | |
---|---|---|---|---|---|
Strong Buy | 4 | 4 | 4 | 4 | 4 |
Buy | 0 | 0 | 0 | 0 | 0 |
Hold | 0 | 0 | 0 | 0 | 0 |
Sell | 0 | 0 | 0 | 0 | 0 |
Strong Sell | 0 | 0 | 0 | 0 | 0 |
ABR | 1.00 | 1.00 | 1.00 | 1.00 | 1.00 |
1. Not Ident. Many of the brokerage firms who provide Zacks data ask that we keep their identity confidential.
2. In most cases the # of brokers listed above is less than the # of brokerage firms that have a recommendation on the stock. That is because some firms prohibit Zacks from displaying detailed information on their recommendations such as in the upgrade/downgrade table.
Analyst Upgrades/Downgrades
Date | Brokerage Firm | Analyst | Previous | Current |
---|---|---|---|---|
3/22/2024 | JMP Securities | Reni Benjamin | Strong Buy | Strong Buy |
3/1/2024 | H.C. Wainwright & Co. | Arthur He | Strong Buy | Strong Buy |
9/28/2023 | SVB Securities | Daina M Graybosch | Strong Buy | Strong Buy |
1. Not Ident. Many of the brokerage firms who provide Zacks data ask that we keep their identity confidential.
2. In most cases the # of brokers listed above is less than the # of brokerage firms that have a recommendation on the stock. That is because some firms prohibit Zacks from displaying detailed information on their recommendations such as in the upgrade/downgrade table.
Average Brokerage Rating
Current ABR | 1.00 |
ABR (Last week) | 1.00 |
# of Recs in ABR | 4 |
Average Target Price | $7.25 |
LT Growth Rate | NA |
Industry | Medical - Biomedical and Genetics |
Industry Rank by ABR | 86 of 252 |
Current Quarter EPS Est: | -0.25 |